Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Mirador Therapeutics develops precision medicines for immune-mediated diseases.
Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.
Designing innovative technologies focused on accelerating global access to biotherapeutics.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
Vizgen provides spatial multi-omics platforms enabling researchers to reveal cellular insights through spatial transcriptomics proteomics.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.
Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Pelage Pharma is a regenerative medicine biotechnology company developing treatments for hair loss.
Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Ollin Biosciences operates as a clinical-stage biopharmaceutical company.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Parabilis Medicines received $305.0M in a Series F round. ARCH Venture Partners's total known invested capital is $22.6B.
ARCH Venture Partners's average investment size is $122.9M across its portfolio of 236 companies.
Recent ARCH Venture Partners portfolio additions include Mirador Therapeutics, bit.bio, Just - Evotec Biologics, Parabilis Medicines, Vizgen. These companies were founded in 2020 or later.